



**2023 Annual Report**  
20 years already!



## Table of content

<b>INTRODUCTION .....</b>	<b>3</b>
<b>OUR ORGANIZATION .....</b>	<b>3</b>
Our mission .....	3
Our vision .....	3
Message from the Chairman of the Board .....	4
Message from the President and CEO .....	5
Our Board of Directors .....	6
Our Founding President .....	7
Our Emeritus Ambassadors and Directors .....	7
Our Spokespersons .....	7
<b>PROSTATE CANCER FINDINGS IN 2023 .....</b>	<b>8</b>
Prostate cancer in numbers .....	9
Prostate cancer risk factors .....	9
<b>OUR EFFORTS TO INFORM AND SUPPORT .....</b>	<b>10</b>
Our dedicated healthcare professionals .....	11
<b>OUR EFFORTS TO CONTRIBUTE TO RESEARCH .....</b>	<b>12</b>
<b>LET'S PLAY, WALK, PEDAL, RIDE, GOLF, CELEBRATE...</b>	
<b>RAISE AWARENESS! .....</b>	<b>13</b>
Hockey Nights PROCURE .....	13
The Walk of Courage PROCURE .....	14
The Tour of Courage PROCURE .....	14
The Ride of Courage PROCURE .....	15
The CEO Challenge PROCURE .....	15
Bowvember PROCURE .....	16
Bow Tie Affair PROCURE .....	17
Auction PROCURE .....	17
Lottery PROCURE .....	18
<b>THE SUPPORT OF AN ENTIRE COMMUNITY .....</b>	<b>19</b>
Our volunteers .....	20
<b>OUR AMBITIONS FOR 2024 .....</b>	<b>21</b>
<b>WHERE YOUR DONATION GOES .....</b>	<b>21</b>
<b>FINANCIAL RESULTS .....</b>	<b>22</b>
Message from the Treasurer .....	22
Independent auditor's report .....	23
Income statement .....	26
Balance sheet .....	27
Complementary note .....	28
Annexe A .....	29

## Introduction

We are delighted to present to you PROCURE's 2023 annual report, which marks the organization's 20<sup>th</sup> anniversary. This document reflects our progress, our determination, and, above all, our collective impact on prostate cancer.

At the heart of our mission lies the belief that hope, education, and support can transform lives. This year, we saw this belief come to life in various forms: in the gratitude of patients, in the unwavering support of our many partners, and in the advancements of medical research. Every step we take, every donation we receive, every word of encouragement shared brings us closer to our common goal: to better treat and cure prostate cancer.

Together, we have built bridges between research and hope, between prevention and support. As we turn the page to a new year, our hope is that this overview of our collective achievements will inspire each of us to redouble our efforts, to share our mission with the world, and to continue making a tangible difference.

With gratitude and determination,  
The PROCURE Team

## About PROCURE

### Our mission

PROCURE is a charitable organization in the fight against prostate cancer. It raises awareness, provides support, and informs those affected by this disease. It promotes and contributes to funding world-class research.

### Our vision

To provide leadership in Quebec in the fight against prostate cancer, to set the standard in the field, and accelerate research to cure the disease.



## Message from the Chairman of the Board

As Chairman of the Board of Directors, I am honored to share with you some reflections on our journey during the year 2023, which also marked the 20<sup>th</sup> anniversary of PROCURE.

Our organization is now a catalyst in the fight against prostate cancer in Quebec. Over the past two decades, we have shown resilience and adaptability in our efforts to improve our impact in the field of prostate cancer. I myself humbly chose to become more involved by accepting the presidency of the board of directors, continuing Marvyn Kussner's vision. We have helped thousands of victims of this cancer and their families, and supported the research community by establishing a world-class biobank.

Today, PROCURE continues to invest in innovative research projects, following the path set by our previous investments in Quebec, with the Terry Fox Foundation and the National Institutes of Health. In 2023, we announced a \$300,000 prostate cancer research grant in partnership with the Foundation of the Quebec Urological Association (QUA). Additionally, PROCURE established a research grant in partnership with the Canadian Urological Association Scholarship Foundation (CUASF). Further significant investments are already planned for the year 2024, demonstrating our continued commitment to research.

I also take this opportunity to commend the excellent work done by our governance and audit committees. Their expertise, commitment, and dedication play an essential role in defining PROCURE's strategic vision and maintaining our highest ethical standards.

Finally, I want to express my deep gratitude to the members of the board of directors. Their sustained involvement and exemplary contributions have been pillars of our success. As we look towards the future, I am confident that the strong foundations we have laid will lead us to new heights. With your continued support, PROCURE will continue to be a beacon of hope and progress, accompanying and improving the quality of life of men and families affected by this disease.

I sincerely thank you for being an integral part of PROCURE's crucial mission.

Cédric Bisson, M.D. and LL.B.  
Chairman of the Board of Directors



## Message from the President and CEO

Over the years, PROCURE has evolved with the times, regularly updating its strategies and tools to better serve its mission. The year 2023 was marked by a significant step towards standardizing our brand image, reflecting our ongoing commitment to coherence and recognition. Our recent technological investments, including the redesign of our website and the improvement of our Customer Relationship Management (CRM) system, perfectly illustrate our desire to remain at the forefront of innovation. These tools not only enhance our internal efficiency but also enrich the experience of all our donors and partners.

Simultaneously, we have diversified our sources of revenue, notably with the introduction of the Lottery PROCURE. This initiative represents a key step in our development, increasing our funds available for research and support, while expanding our donor network.

This year, we have also strengthened our support service by adding multiple resources to our patient helpline, thus responding to growing demand. This development is supported by an ambitious plan to create new tools aimed at improving patient and family support throughout their care journey.

In conclusion, these diversified initiatives underscore PROCURE's unwavering commitment to the fight against prostate cancer. Emphasizing innovation, research, and patient support, we are determined to make a difference, uniting our strengths and knowledge to confidently achieve our goals.



Laurent Proulx  
President and Chief Executive Officer of PROCURE

In 2024, our objectives are clearly defined with clarity and ambition:

- Maximize the use of our technological innovations for increased efficiency.
- Implement a dedicated recognition program for our donors, whether they are businesses or individuals.
- Launch the new visual concept of our website.



## Our Board of Directors

The strength of our board of directors lies in its diversity of expertise. We are privileged to count on the continued contribution of committed individuals, each bringing their unique expertise for the benefit of our organization. We would like to thank all the members of the board of directors for their time, commitment, and generosity throughout the year.



**Cédric Bisson, M.D. and LL.B.**  
**Chairman of the Board**

*Partner, Teralys Capital*



**Salvatore Guerrera**  
**Vice-president**

*President and CEO,  
SAJO*



**Peter Mendell**  
**Secretary**

*Attorney and partner, Davies, Ward,  
Phillips & Vineberg*



**Pierre Vallerand, CPA, CA**  
**Treasurer and Chair of  
the Audit Committee**

*Partner, Raymond Chabot Grant Thornton*



**Marie-Claire Richer**  
**Chair of the Governance Committee**

*Assistant Professor, McGill University  
Executive Director, OIIQ*



**Dr. Armen G. Aprikian**  
**Board member**

*Holder of the Research Chair in Urology  
Professor, Department of Urology,  
McGill (MUHC)*



**Jean-Philippe Duchesneau**  
**Board member**

*Co-owner, Voiles en Voiles  
and Écorécrcéo Group*



**Franco Niro**  
**Board member**

*President, Franco Niro Holdings Inc.*



**Joey Saputo**  
**Board member**

*Owner, CF Montréal and  
Saputo Stadium*



**Jean-Luc Trahan**  
**Board member**

*Consultant, Strategy  
and Communication*



**Dr. Vincent Trudeau**  
**Board member**

*Surgeon-Urologist,  
(CHUR - CIUSSS MCQ)*

## Our Founding President: Marvyn Kussner

PROCURE traces its origins to the vision of one man, Marvyn Kussner, who not only battled his own prostate cancer but also wanted to establish an organization to inform and support those affected by this disease. Twenty years later, we continue our efforts to advance research in this field and to develop new tools to inform patients and their families.

## Our Emeritus Ambassadors and Directors

These honorary titles are awarded in recognition of the exemplary work, commitment, and outstanding philanthropic involvement of individuals who have wholeheartedly supported PROCURE's mission.

Jean Pagé - Michel Côté - Jean de Grandpré - Stephen Jarislowsky - Éric Lamarre  
Alain Lemaire - Malvina Klag - Richard Renaud - Dr. Fred Saad - Dr. Luc Valiquette



Winston McQuade, Isabelle Pagé and Bertrand Godin

## Our Spokespersons

We are deeply touched and honored to count on the passionate commitment of our three dedicated spokespersons: Isabelle Pagé, Bertrand Godin, and Winston McQuade. Their individual contributions, infused with compassion, have illuminated our journey and elevated our mission. Their active involvement, sincere words, and tireless dedication are a living testament to the spirit of solidarity that drives our community.

# Prostate cancer findings in 2023

## Prevalence and incidence

Prostate cancer is the most common cancer in men and remains a major concern. In Quebec, as well as in the rest of Canada, it represents 20% of all new cancer cases in men.



## Screening and diagnosis

Prostate cancer screening is a crucial element in the early detection of the disease, often allowing for better management and more effective treatment options.



## Treatments and prognosis

Thanks to advances in treatments, survival rates for prostate cancer are among the highest of all cancer types. The majority of men diagnosed at an early stage can therefore expect a cure.



## Research and innovation

Research continues to explore new approaches to treatment and screening, including nuclear imaging and precision medicine. Efforts are also being made to better understand genetic and environmental risk factors.



## Social impact


The disease affects the quality of life of patients and their families, particularly in terms of mental health, emotional well-being, and family dynamics. These aspects are often overlooked when discussing the disease in the public sphere and analyzing its societal impact.

These findings underline the importance of the work done by PROCURE to raise awareness, inform, and support men affected by this disease, as well as to encourage research initiatives aimed at improving the prevention, diagnosis, and treatment of prostate cancer.



## Prostate cancer in numbers

In Quebec, there are an average of **6,400\*** new cases of prostate cancer annually. Nationally, these numbers are even more concerning, with **25,900\*\*** new cases reported each year.



## Main risk factors



### Family history

A family history of prostate cancer increases the risk, particularly if the cancer was diagnosed in close male relatives at an early age. Risks are also higher for those with a family history of breast, ovarian, or pancreatic cancer.

**50+**

### Age

Prostate cancer is mainly diagnosed in men over 50, and its prevalence increases with age. Cases before the age of 50 are rare and often linked to genetics.



### Ethnicity

The frequency of prostate cancer varies among populations, being higher in black men, who are also more likely to be diagnosed at an advanced stage and at a younger age compared to white men. Men of Asian descent have the lowest incidence rate.

\* Average calculated from the Statistics of the Quebec Cancer Registry for the data from the 5 most recent years available (2016 to 2020): <https://www.quebec.ca/sante/systeme-et-services-de-sante/organisation-des-services/donnees-systeme-sante-quebecois-services/donnees-cancer>

\*\* Canadian Cancer Statistics Dashboard: <https://cancerstats.ca/>

## Our efforts to inform and support

### Our support services 7 days a week

The initial shock that can accompany a cancer diagnosis is an emotionally intense experience for patients and their families. Many questions arise once leaving the doctor's office, whether it's about understanding the diagnosis, choosing treatments, managing side effects, fear of the unknown, and much more. During this period of vulnerability, having access to a reliable source of information to get answers quickly as well as support is absolutely essential.

That's why PROCURE offers a confidential and toll-free support line, accessible throughout North America 7 days a week, including holidays. Led by uro-oncology specialized nurses, this service represents an essential aspect of our mission. It embodies our unwavering commitment to supporting patients and their families at every stage of their care journey, affirming our role as a cornerstone in the uro-oncology community.

It's clear that our specialized service is a true lifesaver for those

who feel lost in the turmoil of a cancer diagnosis. We are proud of this service and are committed to continuing our efforts to ensure its excellence and availability for all those in need.

### Additional support tools

Throughout the year, we are actively engaged in the continuous development of a diverse range of tools aimed at addressing the various concerns of patients facing prostate cancer. These carefully crafted resources cover a range of essential topics, from medical information to practical advice to improve quality of life. Each tool is subject to approval by our content validation medical committee, ensuring the accuracy and reliability of the information provided. This approach ensures that our patients and their families have access to credible and accurate information, thereby helping to enhance their understanding and support them throughout their cancer experience. We remain committed to expanding our range of tools to meet the evolving needs of our community and to continue to be a reference for all those affected by prostate cancer.

In 2023, we produced and made available for free in both French and English:

- 9 webinars
- 22 blog articles
- 2 animated videos on nuclear medicine
- 3 expert opinion videos
- 3 podcasts
- A 4-week program related to healthy lifestyle habits as part of *Prostate Cancer Awareness Month*

PROCURE maintains total and constant control over the content published, guaranteeing total impartiality in all our productions for the benefit of patients. We are, however, grateful to our various partners for their financial support of our educational program.

## Our dedicated healthcare professionals

We cannot overlook the incredible support we receive from certain healthcare professionals who generously offered their expertise and time in 2023 by being part of our content validation committee. Their voluntary commitment is an essential pillar of our patient information program and significantly contributes to the excellence of our content.

Thanks to their involvement, we are not only able to provide accurate and precise medical information but also produce quality tools on current topics. We are deeply grateful for their selfless contribution and the positive impact they have on our information and support program. Their exemplary collaboration illustrates the great achievements possible when the medical and community sectors work hand in hand. These professionals include:



**Dr. Armen Aprikian**  
Surgeon-Urologist



**Dr. Thierry Dujardin**  
Uro-Oncologist



**Dr. Nawar Hanna**  
Uro-Oncologist



**Dr. Marie-Lyssa Lafontaine**  
Physician, Urology Resident



**Dr. Thierry Lebeau**  
Surgeon-Urologist



**Dr. Malek Meskawi**  
Endo-Urologist



**Dr. Vincent Trudeau**  
Surgeon-Urologist

## Our efforts to contribute to research

Since its foundation, one of PROCURE's main objectives has been to develop a biobank containing biological samples and clinical data to support prostate cancer research. From 2006 to 2013, a little over 2,000 men undergoing prostatectomy for their cancer participated in this biobank at one of the four major university hospitals in Quebec. They agreed to donate blood and urine samples during their periodic follow-up visits, sometimes for over ten years. These samples are a major asset for the PROCURE Biobank, particularly for conducting longitudinal studies, which few other cancer biobanks in the world can offer. Here are three on-going projects currently using samples from our biobank.



INVESTMENT  
**\$2.6M**  
OVER 4 YEARS

### "Molecular Longitudinal Characterization of Lethal Prostate Cancer"

This project is led by Drs. Armen Aprikian and Simone Chevalier from the Research Institute of the MUHC and Dr. Fred Saad from the Research Center of the CHUM. Launched in 2022 and lasting four years, the aim is to identify, among 100 cases of aggressive cancer from the PROCURE Biobank, the driving genes responsible for this cancer by genetically analyzing tumors at the time of surgery and blood samples from these patients from cancer diagnosis

to death. This project represents one of the largest for PROCURE to date, with an investment of \$2.6 million over 4 years.

### "The Steroid Metabolome as a Driving Force for Prostate Cancer Progression"

This research is conducted by Drs. Éric Lévesque, Chantal Guillemette, and Louis Lacombe from the CHU de Québec-Université Laval Research Center. The goal is to determine if certain compounds found in 1948 participants from the PROCURE Biobank could predict disease progression.

### "Artificial Intelligence for Interpreting Prostate Cancer Grades on Histological Images"

This project by Drs. Sami-Ramzi Leyh-Bannurah (St. Antonius Hospital Gronau, Germany) and Dominique Trudel (Research Center of the CHUM) aims to develop a deep learning artificial intelligence

algorithm to better determine the prognosis of prostate cancer.

In 2023, over \$300,000 was awarded in research grants for young researchers in collaboration with the Foundation of the Quebec Urological Association and the Canadian Urological Association Scholarship Foundation. The winners will be announced during the year 2024.

Through funding dedicated to research aimed at improving the quality of life of patients and extending their life expectancy, we continue to support researchers in their innovative approaches.

Thanks to the generosity of our network, PROCURE has provided over \$12 million for prostate cancer research here in Quebec over the past 20 years.



# Let's Play, Walk, Pedal, Ride, Golf, Celebrate... Raise Awareness!

PROCURE is fully committed to raising awareness among the population to remind all men of the importance of taking care of their health. That's why several initiatives are organized throughout the year, all across Quebec. It is also through these activities that we are able to fund all the projects and services offered for the benefit of patients.

## HOCKEY NIGHTS PROCURE

CANCER - PROSTATE

Every year, during January and February, hockey teams from all disciplines (ice hockey, ball hockey, dek hockey) come together to dedicate a game from their regular season to support PROCURE. Leagues of all kinds, whether garage leagues, municipal leagues, or just friendly ones, unite around the cause.

Since 2023, we also have the privilege of including teams under 18 and school leagues. This already promises a bright future for this campaign, now in its 4<sup>th</sup> edition!



## Thank you to our partners and sponsors

Captodor - CF Montréal - Cogeco Média - Distribution Stox - Hockey Québec - IG Gestion Patrimoine - La Caisse de bienfaisance des employés et retraités du CN - Spordle



## THE WALK OF COURAGE PROCURE

CANCER - PROSTATE

Now in its 17<sup>th</sup> edition, The Walk of Courage PROCURE, in memory of Jean Pagé, is a unifying and family-friendly event that has made its mark in the hearts and traditions of Quebec families affected by the disease. Across Quebec, many have participated by walking with their loved ones on Father's Day, in support or in memory of a dear one affected by prostate cancer.

CF Montréal supports PROCURE on numerous occasions throughout the year, but we would particularly like to highlight their constant commitment and unwavering support from one edition to the next of The Walk of Courage PROCURE.



## THE TOUR OF COURAGE PROCURE

CANCER - PROSTATE

As a sign of solidarity, the 14<sup>th</sup> edition of the Tour of Courage PROCURE took place across Quebec over a period of 30 days, and also in person on the famous Camilien-Houde climb on Mount Royal. In distance and/or elevation gain, all participating cyclists showed resilience and determination. An event that, year after year, seems to constantly push the limits of endurance for our loyal participants.



### Thank you to our partners and sponsors

AstraZeneca - Bicycles Quilicot  
Biemme - Bottecchia - CF Montréal  
Jean Coutu - Merck - Velo Mag



## THE RIDE OF COURAGE PROCURE CANCER - PROSTATE

In September, as part of Prostate Cancer Awareness Month, The Ride of Courage PROCURE allows us to reach out to motorcycle enthusiasts. Thanks to dedicated partners, we have been able to promote this campaign throughout the province and reach a new group of donors, which is expected to grow year after year. It has now become an annual event from September 1<sup>st</sup> to 30<sup>th</sup> to ride for the cause!



**Thank you to our partners and sponsors**

Fédération Motocycliste du Québec - Intact Assurance - Moto Journal - Moto Québec - TECNIC



## DÉFI PDG PROCURE CANCER - PROSTATE

The CEO Challenge (Défi du PDG) is an initiative launched by PROCURE's President and CEO, Mr. Laurent Proulx. Those who know him are aware that he never proposes easy challenges! Whether in a professional context or in his sports activities, Mr. Proulx is known for his ability to constantly push boundaries. Those willing to follow him must possess strong resilience, unwavering determination, and excellent physical condition. Over the past few years, many regular participants have joined Mr. Proulx in cycling the distance between Montreal and Quebec City, passing through the four university hospitals, all accomplished in less than 24 hours, covering 382 km.

**Thank you to our partners and sponsors**

Bicycles Quilicot - CF Montréal - Premium VR



## An emblematic campaign

The Bowvember campaign, a central element of our awareness efforts, achieved significant success in its 10<sup>th</sup> year. The events organized throughout the month of November and innovative initiatives by participants and strategic partners, along with the involvement of several well-known public figures, contributed to raising the profile of this emblematic campaign, making this period a key moment in the year.

This year was particularly marked by an unprecedented mobilization following the death of Karl Tremblay, the highly acclaimed lead singer of the Cowboys Fringants. His passing deeply moved and prompted a wave of solidarity, intensifying calls to our support line at PROCURE.

### Thank you to our partners and sponsors

Aon - ArcelorMittal Produits longs Canada - Archer - Association des pompiers de Montréal  
 AstraZeneca - CF Montréal - Club Med - CN - Distribution Stox - Ernest - Fairmont - Germain Hôtels  
 Gray Collection - Greiche & Scaff - Jonathan - Kinessor - La Presse - Mantra Pharma - Merck  
 Michelin Canada - Obliques média - Outfront - Pfizer - Point S Canada - Pompe Média - Québecor  
 Remparts de Québec - SAQ - Sheraton Laval - Simons - Structurack



## BOW TIE AFFAIR PROCURE

CANCER - PROSTATE

The Bow Tie Affair is a festive event where the spirit of solidarity and commitment shines brightly. Guests, each driven by a personal connection to the cause, come together to make this event a powerful expression of support.

Thank you to all who made this evening possible and who continue to make our cause a shared priority.



## AUCTION PROCURE

CANCER - PROSTATE

Every year, our team dedicates itself to organizing an extraordinary auction event, and 2023 was no exception. With the generosity and commitment of our many partners and donors, we were able to offer a diverse selection of items, from unique experiences to coveted collectibles.

### Thank you to our partners and sponsors

Alliance de Montréal - Alouettes de Montréal - Bâton Rouge - CasaM Food Truck - CF Montréal - Club de Golf Rosemère - Golf Fontainebleau - Club Med - CRAFT sportswear - évoilà5 Rosemère & Terrebonne - Fairmont Hotels and Resorts - Golf St-Raphaël - Hébergia - Idolem Yoga Chaud - La vie en rose & Bikini Village - Lambert - Médspa Victoria Park - Nautilus Plus - Patrick Morin - Rocket de Laval - Scandinave spa - Sports Expert Centre-ville - Structurack - Tim Hortons

# LOTTERY PROCURE


CANCER – PROSTATE

In 2023, we had the great privilege of launching our very first PROCURE lotteries, which sparked enthusiasm and engagement throughout our network.

Among the prizes, a VIP trip to Bologna, Italy, was up for grabs, offering the lucky winner a unique experience, steeped in culture, gastronomy and unforgettable activities. In a second lottery, it is a electric vehicle Ford Mustang Mach-E which was offered.

These remarkable achievements were made possible thanks to the support and generosity of our partners, ensuring that every dollar raised is directly allocated to our cause. This comprehensive contribution has significantly strengthened our ability to support innovative research and essential information and support programs for patients and their loved ones.

Congratulations to our winners!



Thank you to our partners  
CF Montréal - Fondation  
Norman Fortier - Fortier Ford  
- Distribution Stox







## The support of an entire community

We are deeply grateful to an exceptional community of committed people who, on their own initiative, organize fundraisers for PROCURE.

These passionate and dedicated individuals valiantly set up various fundraising activities, whether golf tournaments, benefit dinners, discounts on product sales or many other imaginative ideas to sup-

port our mission.

These multiple independent initiatives allow us to strengthen our local commitment, extend our reach and get in touch with people affected by the cause, as well as potential donors, across several regions of Quebec.

We thank all these people who, thanks to their determination to make a difference and to rally

their network around our cause, propel our organization and significantly help us in our goal of raising awareness of an ever-increasing number of people.

Their contribution goes well beyond monetary figures; it tangibly fuels our mission and brings to life our vision of a future where prostate cancer is no longer such a daunting threat.





# Our volunteers

To every volunteer who dedicated their time and energy to our cause in 2023, we extend our sincerest thanks. Your commitment is a source of inspiration, and we are grateful to have such exceptional individuals supporting us.





# In the coming year, our ambitions and objectives will be characterized by innovation and commitment.

Technology, at the heart of our strategy, will play a crucial role in our mission. It will be the essential tool to expand our community, improve our communication, and ensure the sustainability of our actions. We intend to maximize the use of digital tools to strengthen our presence and impact, reaching a broader and more diverse audience.

We also intend to strengthen our


corporate partnership strategy by offering even more webinars in businesses to raise awareness among employers and employees about this male cancer. With this approach, we hope to convince men to take care of their health.

In 2024, we will continue our strong commitment to research. Not only will we award research grants to young researchers here, but we also aspire to fund several major

and innovative projects that promise significant advances in the field of prostate cancer.

With your unwavering support, we will continue our quest to make a real and concrete difference in the lives of men affected by prostate cancer and their families. We are determined to achieve our goals and continue to advance the cause that unites us. Having you by our side is more precious than ever.

## Where your donation goes



## 2023 financial results

### Message from the Treasurer

As Treasurer of PROCURE, I present to you the financial results for the year 2023 with a deep sense of responsibility. Thanks to the extraordinary generosity of our donors, we have been able to continue effectively supporting the fight against prostate cancer.

This year, we had the pleasure of collaborating with a new audit firm, MNP, which brought a fresh and rigorous perspective to the analysis of our finances. This transition is part of our ongoing commitment to transparency and the prudent management of the funds entrusted to us.

We continue to optimize every dollar received, ensuring that the largest possible portion of our resources is allocated directly to support and research programs. The financial statements for the fiscal year ending December 31, 2023, prepared in accordance with Canadian accounting standards for non-profit organizations, attest to our determination to maintain the highest financial integrity.

Your support is precious and vital to our mission. On behalf of the entire team and the people we help, I sincerely thank you. Together, we are making a real and lasting difference in the lives of many people affected by prostate cancer.



Pierre Vallerand, CPA, CA  
Treasurer and Chair of the Audit Committee  
Partner, Raymond Chabot Grant Thornton

# Independent Auditor's Report

## Qualified Opinion

We have audited the accompanying financial statements of ALLIANCE PROCURE (the "Organization"), which comprise the balance sheet as at December 31, 2023, and the statements of operations, changes in net assets and cash flows for the year then ended, and the related notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the "Basis for Qualified Opinion" section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at December 31, 2023 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

## Basis for Qualified Opinion

Like many not-for-profit organizations, the organization derives income from fundraising activities, the completeness of which it is not possible to audit satisfactorily. Consequently, our audit of these revenues was limited to the amounts recorded in the organization's accounts, and we were unable to determine whether any adjustments might need to be made to the amounts of fundraising revenues, excess of revenues over expenses and cash flows from operating activities for the year ended December 31, 2023, current assets and current liabilities as at December 31, 2023, and net assets as at January 1, 2023 and December 31, 2022. The predecessor expressed a modified audit opinion on the financial statements for the year ended December 31, 2022, due to the potential impact of this scope limitation.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under these standards are more fully described in the section of this report entitled "Auditor's Responsibilities for the Audit of Financial Statements". We are independent of the Organization in accordance with the rules of professional conduct applicable to the audit of financial statements in Canada, and have fulfilled our other ethical responsibilities under those rules. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

## Other Point

Alliance Procure's financial statements for the period ended December 31, 2022 were audited by another auditor who expressed a qualified opinion on these statements on April 4, 2023 for the reasons described in the "Basis for Qualified Opinion" paragraph.

## **Responsibilities of Management and Those Charged with Governance with respect to the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing any going concern issues and applying the going concern basis of accounting, unless management intends to liquidate the Organization or cease operations, or if there is no realistic alternative.

Those charged with governance are responsible for overseeing the organization's financial reporting process.

## **Auditor's Responsibilities for the Audit of Financial Statements**

Our objectives are to obtain reasonable assurance that the financial statements taken as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report containing our opinion. Reasonable assurance represents a high level of assurance, but does not guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect all material misstatements. Misstatements may result from fraud or error and are considered material when it is reasonable to expect that, individually or in aggregate, they could influence the economic decisions that users of the financial statements make in reliance on them.

In an audit conducted in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and critical thinking throughout the audit. In addition:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures in response to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our audit opinion. The risk of not detecting a material misstatement resulting from fraud is higher than that of a material misstatement resulting from error, as fraud may involve collusion, falsification, deliberate omission, misrepresentation or circumvention of internal control.
- Obtain an understanding of the internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of the accounting policies used and the reasonableness of accounting estimates made by management, as well as the related disclosures made.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether there is any material uncertainty related to events or circumstances that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw the attention of the readers of our report to the disclosures in the financial statements about that uncertainty or, if those disclosures are not adequate, to express a modified opinion. Our conclusions are based on evidence obtained up to the date of our report. Future events or circumstances could cause the Organization to cease operations.



- Evaluate the overall presentation, structure and content of the financial statements, including the information provided in the notes, and assess whether the financial statements give a true and fair view of the underlying transactions and events.

In particular, we communicate to those charged with governance the planned scope and timing of the audit work and our significant findings, including any material weaknesses in internal control that we may have identified during the course of the audit.



*MNP* SENCRL, s.r.l.<sup>1</sup>

Montreal (Quebec), April 17, 2024

S.E.N.C.R.L., s.r.l./LLP  
8200, boul. Décarie, bureau 190, Montreal (Quebec) H4P 2P5  
Tel. : 514.933.8611 Fax : 514.933.1142 MNP.ca

<sup>1</sup>By CPA auditor, public accounting permit no. A111929

# Income statement

	2023	2022
	\$	\$
<b>REVENUES</b>		
<b>Fundraising Activities</b>		
Donations from individuals	617 884	476 976
Donations from companies	433 311	282 210
Donations from foundations	320 200	263 594
Sponsorships	358 150	407 555
	<b>1 729 545</b>	<b>1 430 335</b>
<b>Other Revenues</b>		
Merchandise sold	475 126	373 953
Lottery revenues	205 234	-
Investment revenues	52 071	14 513
Other revenues	34 266	36 853
	<b>766 697</b>	<b>425 319</b>
<b>Total revenues</b>	<b>2 496 242</b>	<b>1 855 654</b>
<b>EXPENSES (Annex A)</b>		
Awareness, education and support programs	1 226 897	982 094
Material for resale	290 523	205 500
Biobank	372 810	367 291
Administration	100 340	147 864
<b>Total expenses</b>	<b>1 990 571</b>	<b>1 702 749</b>
<b>Excess of revenues over expenses</b>	<b>505 671</b>	<b>152 905</b>

# Balance sheet

	2023	2022
	\$	\$
<b>ASSETS</b>		
<b>Short term</b>		
Cash	1 258 064	912 380
Investments	1 273 541	1 221 727
Accounts receivable	131 211	103 079
Prepaid expenses	-	7 551
	<b>2 662 816</b>	<b>2 244 737</b>
<b>Tangible and intangible fixed assets</b>	<b>1 862</b>	<b>12 682</b>
<b>Guarantee deposit</b>	<b>17 500</b>	<b>5 000</b>
<b>Total assets</b>	<b>2 682 178</b>	<b>2 262 419</b>
<b>LIABILITIES</b>		
<b>Short term</b>		
Accounts payable	105 124	172 911
Deferred income	25 000	43 125
	<b>130 124</b>	<b>216 036</b>
<b>Long term debt</b>	<b>40 000</b>	<b>40 000</b>
<b>Total liabilities</b>	<b>170 124</b>	<b>256 036</b>
<b>NET ASSETS</b>		
Internal assignments (research funds) - See note 1	1 500 000	1 500 000
Unrestricted net assets	1 010 192	493 701
Invested in assets	1 862	12 682
	<b>2 512 054</b>	<b>2 006 383</b>
<b>Total liabilities and net assets</b>	<b>2 682 178</b>	<b>2 262 419</b>



# Complementary note

## Note 1 - Internal assignment

During the year, the organization's Board of Directors made the following internal allocations:

	Balance December 31 2022	Assignment during year	Use during year	Balance December 31 2023
	\$	\$	\$	\$
Research fund*	1 500 000	-	-	1 500 000
	1 500 000	-	-	1 500 000

### \*Committed investments

In 2022, PROCURE signed a 4-year agreement with the Marathon of Hope Cancer Centres Network and the Cedars Cancer Foundation for one million dollars, or \$250,000 per year until December 31, 2025. This funding will be used to characterize the genetic alterations of 100 prostate cancer patients from PROCURE's Biobank, in order to carry out a large-scale genomic analysis of the lethal form of prostate cancer. The commitment balance at December 31, 2023 is \$500,000.

In 2023, PROCURE announced the launch of a \$300,000 research grant in partnership with the Foundation of the Quebec Urological Association (QUA), an organization dedicated to improving the prevention, diagnosis and treatment of urological diseases, including prostate cancer. The award will fund two prostate cancer research projects, each to a maximum of \$50,000, for a total of \$100,000 per year over three years. The commitment balance for the PROCURE-QUA partnership at December 31, 2023 is \$150,000.

Also in 2023, PROCURE announced the launch of a new research grant in partnership with the Canadian Urological Association Scholarship Foundation (CUASF), an organization dedicated to improving the prevention, diagnosis and treatment of urological diseases, including prostate cancer. PROCURE will donate \$75,000 and CUASF will match this amount for a total commitment of \$150,000. The remaining commitment for the PROCURE-CUASF partnership at December 31, 2023 is \$82,500.

### Future investment

In 2024, PROCURE and the Cancer Research Society (CRS) will jointly invest a total of two million dollars at a ratio of 1:1 (\$1M from PROCURE and \$1M from CRS) to fund, over a three (3) year grant period (fiscal years 2025-2026 to 2027-2028), proposals qualifying for a grant following the recommendations of a peer review panel. PROCURE and the CRS wish to fund up to four (4) research projects focused on prostate cancer.

# Annex A

2023 2022

	Awareness, education and support programs	Material for resale	Biobank	Administration		
<b>Expenses</b>	\$		\$	\$	\$	\$
Salaries and social charges	613 950		56 924	14 032	<b>684 906</b>	604 649
Logistics services	71 709		-	803	<b>72 512</b>	79 859
Merchandise for resale	-	290 523	-	-	<b>290 523</b>	205 500
Event expenses	266 525		-	10 911	<b>277 436</b>	193 421
Office expenses	74 806		-	12 766	<b>87 572</b>	82 389
Professional services	37 596		-	28 006	<b>65 602</b>	79 815
Consultants	93 141		-	5 052	<b>98 193</b>	71 480
Rental expenses	41 920		3 260	1 397	<b>46 577</b>	43 653
Transaction costs	17 555		-	3 065	<b>20 620</b>	13 431
Telecommunications	3 680		-	8 590	<b>12 270</b>	11 038
IT development	5 059		-	842	<b>5 901</b>	6 394
Insurance	956		-	2 772	<b>3 728</b>	5 489
Training and development	-		-	4 422	<b>4 422</b>	658
Amortization of tangible fixed assets	-		-	5 441	<b>5 441</b>	7 409
Amortization of intangible assets	-		-	2 241	<b>2 241</b>	4 482
	1 226 897	290 523	60 184	100 340	<b>1 677 945</b>	1 409 667
Contributions to hospital centers	-	-	312 626	-	<b>312 626</b>	293 082
	1 226 897	290 523	372 810	100 340	<b>1 990 571</b>	1 702 749



110-1320 boul Graham  
Mont-Royal (QC) H3P 3C8

**1 855 899-2873 | [procure.ca](http://procure.ca)**

86394 4955 RR0001